Kymera Therapeutics has reported positive results from a Phase I clinical trial of its lead programme, KT-474 (SAR444656), for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD).

KT-474 is a degrader of IRAK4, a protein that activates toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs) causing inflammation.

It blocks TLR/IL-1R-mediated inflammation more effectively compared to monoclonal antibodies targeting single cytokines.

KT-474 also abolishes both the kinase and scaffolding functions of IRAK4 and is said to be superior to IRAK4 kinase inhibitors.

In a Phase I trial, KT-474 demonstrated robust IRAK4 degradation in skin and blood lesions and showed systemic anti-inflammatory effect in HS and AD patients.

KT-474 was also found to be well-tolerated and showed similar safety, pharmacokinetics and pharmacodynamics properties as showed by healthy volunteers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A highly competitive profile with substantial responses in majority of patients with moderate-to-severe HS and AD was also observed in the study.

Kymera Therapeutics chief medical officer Jared Gollob said: “KT-474 exhibited clinical activity in HS and AD patients that we believe is superior to IRAK4 small molecule kinase inhibitors and appears competitive with standard of care biologics and other agents in development in both HS and AD.

“These results validate IRAK4 degradation as a potential best-in-class mechanism in TLR/IL-1R-driven inflammatory diseases that has the potential to improve the lives of patients with conditions like HS and AD and potentially other indications.

“We look forward to sharing additional updates as our partner Sanofi initiates Phase II clinical trials of KT-474 in HS and AD, with the first study in HS planned for initiation in 2023.”